O-GlcNac Modified Proteomics Study of the Maturation of Hemodialysis Arteriovenous

NCT05832476 | Completed

• 1 other identifier: 201712231RINC
• Study Type: observational
• Target: 126
• Locations: 1 country
• Sites: 1

Brief Summary

We divided into three parts to carry out. Firstly, evidence the pre-existing fibrosis in vein of AVF failure patients. investigation of expression, the role, and the mechanism by which the identified O-GlcNAac proteins promote, maturation of AV fistula. Finally, ddress and compare the proteomics differentiation between failure and maturation of AVF patients.

Conditions

Arteriovenous Fistula Occlusion

Keywords

Arteriovenous Fistula; vascular smooth muscle; histological technique; O-GlcNac; proteomics

Outcome Measures

Primary Outcomes (1)

• The diameter of each passage of the passage vein (forearm head vein) of the arterial and venous access within three months

  Comparison of the various methods to achieve within three months the checkpoint path diameter increase rate (two time points measurement difference).

  Postoperative Three months

Study Arms (2)

Matured

It is defined as the target HDAVF can be used

Other: No intervention

Non-matured

RC-AVF underwent additional intervention after 90 days of observation

Other: No intervention

Interventions

No intervention OTHER

No intervention

Matured; Non-matured

Eligibility Criteria

• Age: 20 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Age of 20 and older adult patients, and preoperatively clinical and ultrasound assessment of the arm vessels are fisible for the creation of a native HDAVF that include:the augmented diameters of the veins is \> 2.0 mm and the diameter of the radial artery is\> 2.0 mm. Besides, there is no obvious stenosis of vessels in the forearm.

You may qualify if:

• Age of 20 and older adult patients, and preoperatively clinical and ultrasound assessment of the arm vessels are fisible for the creation of a native HDAVF that include:the augmented diameters of the veins is \> 2.0 mm and the diameter of the radial artery is\> 2.0 mm. Besides, there is no obvious stenosis of vessels in the forearm.

You may not qualify if:

• The patient refused to join the study
• Too weak
• Serious heart failure
• Unconsciousness
• Bedridden for long time
• systemic lupus erythematosus(SLE), or other known autoimmune diseases
• The physician excludes the possibility of creating a wrist HDAVF before surgery
• Surgeon preoperatively identifies vessel inadequacy for the creation of a wrist HDAVF
• Choose a site other than the wrist for surgery
• Unexpected negative complications happen during surgery that prevent the completion of a wirst HDAVF

Sponsors & Collaborators

• National Taiwan University Hospital: lead

Study Sites (1)

National Taiwan University Hospital

Taipei, No.7, Chung Shan S. Rd, 10002, Taiwan

Location

MeSH Terms

Conditions

Arteriovenous Fistula

Condition Hierarchy (Ancestors)

Arteriovenous Malformations; Vascular Malformations; Cardiovascular Abnormalities; Cardiovascular Diseases; Vascular Fistula; Vascular Diseases; Congenital Abnormalities; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Fistula; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms

Study Officials

• Chih-Yang Chan, phd

  National Taiwan University Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 12 Months
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 14, 2023
• First Posted: April 27, 2023
• Study Start: March 28, 2018
• Primary Completion: October 26, 2020
• Study Completion: October 26, 2020
• Last Updated: April 27, 2023

Record last verified: 2018-01

Data Sharing

• IPD Sharing: Will share

Locations

TW (1)